Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	FGFR2 act mut
Gene Variant Detail	FGFR2 act mut (gain of function)
Relevant Treatment Approaches	FGFR Inhibitor (Pan) FGFR2 Inhibitor

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial	Phase	Therapies	Title	Recruitment Status	Covered Countries	Other Countries
NCT05627063	Phase I	ABSK121	A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors	Recruiting	USA	1
NCT05267106	Phase II	Pemigatinib	Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations (FIGHT-209)	Active, not recruiting	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DNK \| DEU	1
NCT03767075	Phase II	Amivantamab-vmjw Futibatinib Atezolizumab	A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)	Recruiting	SWE \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU	0
NCT04096417	Phase II	Pemigatinib	Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations	Active, not recruiting	USA	0
NCT06302621	Phase I	Afatinib + Pemigatinib	Pemigatinib + Afatinib in Advanced Refractory Solid Tumors	Recruiting	USA	0
NCT02052778	Phase Ib/II	Futibatinib	A Study of TAS-120 in Patients With Advanced Solid Tumors	Completed	USA \| NLD \| ITA \| GBR \| FRA \| ESP \| DEU \| CAN \| AUS	4
NCT04963153	Phase I	Enfortumab vedotin-ejfv + Erdafitinib	Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy	Recruiting	USA \| CAN	0
NCT01975701	Phase II	Infigratinib	A Phase 2 Study of BGJ398 in Patients With Recurrent GBM	Completed	USA \| NLD \| ESP \| CHE \| BEL \| AUS	0
NCT04923126	Phase Ib/II	PD-0325901	SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma	Recruiting	USA	0
NCT06160752	Phase I	TYRA-200	Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations (SURF201)	Recruiting	USA	0
NCT03827850	Phase II	Erdafitinib	FGFR Inhibitor in FGFR Dysregulated Cancer (FIND)	Terminated	DEU	0
NCT05253807	Phase II	Pemigatinib	Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration (FIGHT-210)	Completed	USA \| ITA \| FRA \| ESP \| DEU	0
NCT03822117	Phase II	Pemigatinib	Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)	Terminated	USA \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CHE	2
NCT06319820	Phase III	Mitomycin C Gemcitabine Erdafitinib	A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)	Recruiting	USA \| TUR \| POL \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| BRA \| BEL \| AUT \| ARG	4
NCT01888562	Phase I	Ponatinib	Ponatinib in the Treatment of FGFR Mutation Positive Recurrent or Persistent Endometrial Carcinoma	Withdrawn		0
NCT03390504	Phase III	Pembrolizumab Erdafitinib Docetaxel + Vinflunine	A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations (THOR)	Active, not recruiting	USA \| TUR \| POL \| NLD \| ITA \| ISR \| HUN \| GRC \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG	8
NCT05159245	Phase II	Vemurafenib Tepotinib Vismodegib Apalutamide Alectinib Regorafenib Entrectinib Pertuzumab + Trastuzumab Pemigatinib Atezolizumab Cobimetinib Dabrafenib + Trametinib Dabrafenib Trametinib Abemaciclib	The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)	Recruiting	FIN	0
NCT05316155	Phase I	Erdafitinib	Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer	Recruiting	USA \| NLD \| ESP \| DEU	1
NCT02272998	Phase II	Ponatinib	Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.	Active, not recruiting	USA	0